{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:55:40Z","timestamp":1760244940000},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12308-008-0014-8","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T07:21:57Z","timestamp":1219821717000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The implication of identifying JAK2\n                     \n                V617F\n               in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Randall J.","family":"Olsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherie H.","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis P.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April A.","family":"Ewton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Che","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097","journal-title":"Blood"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MOH.0b013e32801684d9","volume":"14","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Vardiman JW (2007) The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Current opinion in hematology 14:115\u2013122","journal-title":"Current opinion in hematology"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.5858\/2006-130-1151-CMOTMD","volume":"130","author":"L Rice","year":"2006","unstructured":"Rice L, Baker KR (2006) Current management of the myeloproliferative disorders: a case-based review. Arch Pathol Lab Med 130:1151\u20131156","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162\u20132168","journal-title":"Blood"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2141.2006.06483.x","volume":"136","author":"F Passamonti","year":"2007","unstructured":"Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M (2007) JAK2 (V617F) mutation in healthy individuals. Br J Haematol 136:678\u2013679","journal-title":"Br J Haematol"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131:208\u2013213","journal-title":"Br J Haematol"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","volume":"106","author":"RL Levine","year":"2005","unstructured":"Levine RL, Loriaux M, Huntly BJ, Loh M, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen K, Flores N, Estey E, Gattermann N, Armstrong S, Look TA, Griffin JD, Bernard OA, Gilliland DG, Druker BJ, Deininger MW (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377\u20133379","journal-title":"Blood"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.seminhematol.2005.05.019","volume":"42","author":"ZJ Zhao","year":"2005","unstructured":"Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN (2005) Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol 42:221\u2013229","journal-title":"Semin Hematol"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D (2005) The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131:320\u2013328","journal-title":"Br J Haematol"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG (2005) Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131:166\u2013171","journal-title":"Br J Haematol"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1365-2141.2005.05719.x","volume":"130","author":"MF Johan","year":"2005","unstructured":"Johan MF, Goodeve AC, Bowen DT, Frew ME, Reilly JT (2005) JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia. Br J Haematol 130:968","journal-title":"Br J Haematol"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","volume":"130","author":"S Sulong","year":"2005","unstructured":"Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J (2005) The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. Br J Haematol 130:964\u2013965","journal-title":"Br J Haematol"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05682.x","volume":"130","author":"TL Lasho","year":"2005","unstructured":"Lasho TL, Mesa R, Gilliland DG, Tefferi A (2005) Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 130:797\u2013799","journal-title":"Br J Haematol"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.5858\/2006-130-1133-CIM","volume":"130","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Chang CC (2006) Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis. Arch Pathol Lab Med 130:1133\u20131143","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.5858\/2006-130-1126-PV","volume":"130","author":"M Cao","year":"2006","unstructured":"Cao M, Olsen RJ, Zu Y (2006) Polycythemia vera: new clinicopathologic perspectives. Arch Pathol Lab Med 130:1126\u20131132","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.5858\/2006-130-1144-ET","volume":"130","author":"S Sanchez","year":"2006","unstructured":"Sanchez S, Ewton A (2006) Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med 130:1144\u20131150","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5858\/2006-130-997-DOTJMI","volume":"130","author":"RJ Olsen","year":"2006","unstructured":"Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC (2006) Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 130:997\u20131003","journal-title":"Arch Pathol Lab Med"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/modpathol.3800826","volume":"20","author":"P Hsieh","year":"2007","unstructured":"Hsieh P, Olsen RJ, O\u2019Malley DP, Konoplev S, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC (2007) The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol 20:929\u2013935","journal-title":"Mod Pathol"},{"key":"14_CR22","first-page":"1128","volume":"90","author":"J Thiele","year":"2006","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2006) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128\u20131132","journal-title":"Haematologica"},{"key":"14_CR23","volume-title":"Tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC), Lyon, France"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF02982575","volume":"76","author":"JJ Michiels","year":"2002","unstructured":"Michiels JJ, Thiele J (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133\u2013145","journal-title":"Int J Hematol"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0145-2126(02)00098-X","volume":"27","author":"DP Steensma","year":"2003","unstructured":"Steensma DP, Tefferi A (2003) The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 27:95\u2013120","journal-title":"Leuk Res"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459\u2013468","journal-title":"N Engl J Med"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood-2006-04-014712","volume":"108","author":"T Mercher","year":"2006","unstructured":"Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG (2006) JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108:2770\u20132779","journal-title":"Blood"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207\u20131209","journal-title":"Blood"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106:3370\u20133373","journal-title":"Blood"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","volume":"106","author":"RL Levine","year":"2005","unstructured":"Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377\u20133379","journal-title":"Blood"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664\u20132670","journal-title":"Blood"},{"key":"14_CR32","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, Richards MA, Moller H, Schey SA (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 91:1400\u20131404","journal-title":"Haematologica"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","volume":"19","author":"K Ohyashiki","year":"2005","unstructured":"Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, Ohyashiki JH (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359\u20132360","journal-title":"Leukemia"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.leu.2404231","volume":"20","author":"M Kremer","year":"2006","unstructured":"Kremer M, Horn T, Dechow T, Tzankov A, Quintanilla-Martinez L, Fend F (2006) The JAK2 V617F mutation occurs frequently in myelodysplastic\/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia 20:1315\u20131316","journal-title":"Leukemia"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-008-0014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-008-0014-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12308-008-0014-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-008-0014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:52:48Z","timestamp":1630439568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-008-0014-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s12308-008-0014-8","relation":{},"ISSN":["1865-5785","1865-5785"],"issn-type":[{"value":"1865-5785","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]},"assertion":[{"value":"16 June 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"111"}}